BNP Paribas Financial Markets acquired a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 122,373 shares of the company's stock, valued at approximately $2,554,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Crossmark Global Holdings Inc. boosted its stake in shares of Genmab A/S by 8.8% during the 4th quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company's stock worth $868,000 after purchasing an additional 3,377 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Genmab A/S by 82.7% during the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company's stock valued at $551,000 after buying an additional 11,949 shares during the period. Blue Trust Inc. boosted its position in Genmab A/S by 33.4% during the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after acquiring an additional 1,442 shares during the last quarter. R Squared Ltd acquired a new stake in Genmab A/S during the fourth quarter worth approximately $93,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after acquiring an additional 827 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.
Genmab A/S Stock Performance
GMAB traded up $0.56 during trading on Thursday, reaching $21.08. The company had a trading volume of 449,612 shares, compared to its average volume of 1,117,754. The firm's 50-day simple moving average is $19.75 and its 200 day simple moving average is $20.72. The company has a market cap of $13.51 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 2.65 and a beta of 1.04. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.06.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The company had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. On average, sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the company. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Truist Financial dropped their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S presently has an average rating of "Moderate Buy" and an average target price of $39.17.
Check Out Our Latest Stock Report on Genmab A/S
About Genmab A/S
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
